Navigation Links
Prasco® Selected as Eli Lilly and Company's Authorized Generics Partner
Date:10/20/2011

CINCINNATI, Oct. 20, 2011 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic version of ZYPREXA® (olanzapine) Tablets and ZYPREXA® ZYDIS (olanzapine) Orally Disintegrating Tablets, in the U.S.

Prasco will begin distribution of both products upon the first ANDA entrant into the market.  Prasco will market all six strengths of Olanzapine Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg.  Olanzapine Orally Disintegrating Tablets will be available in 5 mg, 10 mg, 15 mg, and 20 mg strengths. The financial terms of the agreement were not disclosed.

"Prasco's passion to bring high quality, low cost prescription drugs to consumers continues to expand," said Prasco Chief Executive Officer E. Thomas Arington. "We are especially excited to welcome Eli Lilly and Company to our Prasco family of partners."

Prasco is established as the Authorized Generics company, having brought more Authorized Generics to market than any other company by offering generic products that are identical to the Brand product. "Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the Olanzapine launch through our new Lilly relationship," Arington concluded.  

Olanzapine Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA.  Olanzapine Orally Disintegrating Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA ZYDIS.  

For additional information about ZYPREXA and ZYPREXA ZYDIS, please see Full Prescribing Information including Box Warning at http://pi.lilly.com/us/zyprexa-pi.pdf and Medication Guide at http://pi.lilly.com/us/zyprexa-medguide.pdf.

About Prasco Laboratories - Prasco, the Authorized Generics company, is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics. Prasco Authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit www.prasco.com.

For additional information about ZYPREXA and/or ZYPREXA ZYDIS, please contact:  Stefanie Prodouz, Manager, Lilly Bio-Medicines Communications | 317.224.5331.


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco® Launches Authorized Generic with Shionogi Inc.
2. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
3. Prasco Named Exclusive U.S. Distributor for Selected Aspen Branded Products
4. Christine Pierre Selected as "Professional Woman of the Year"
5. Dr. Paul Farmer Selected as 2011 Pro Bono Humanum Honoree by Prix Galien USA
6. Coloplast Selected By LifeScience Alley to Host Minnesota Medical Device Panel
7. BioSurplus Selected to Auction $10 Million in Lab Equipment
8. Linet Multicare® Hospital Bed Selected to Participate in National Program Highlighting Commitment to Healthcare Performance Improvement, Innovation
9. Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award
10. Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
11. Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):